Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.55 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42974 | 0.98 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Bromide SCHEMBL7209454 | 0.96 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Ethylene SCHEMBL29161557 | 0.94 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Hydrochloric Acid SCHEMBL3885829 | 0.94 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL29901844 | 0.91 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL27544552 | 0.91 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL8758619 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Toluene SCHEMBL27392908 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL22830136 | 0.88 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Hydrochloric Acid SCHEMBL7367924 | 0.86 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 826 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011119-A | Preparation method and application of bionic collagen cyclohexapeptide | 成都欣肽生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-119775348-A | Preparation method of polypeptide Angstrom Pi Dalong acetate | 深圳市第二人民医院(深圳市转化医学研究院) | 2025-04-08 | — | — | CN | claimed |
| CN-119219500-A | Intermediate of 2, 3-dimethylcyclopropylcarboxylic acid and synthetic method thereof | 南通诺泰生物医药技术有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-119019539-A | Iterative index synthesis method of long-chain collagen-like polypeptide | 上海欣肽生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118085016-B | Preparation method of D-phenylglycinyl-glycine | 天津卡普希科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-221317714-U | Low-temperature storage tank prepared from benzyl glycine hydrochloride | 四川安派博生物科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118125979-A | Ionizable lipid JK-0043, preparation method, application and LNP encapsulation preparation method | 宁波君健生物科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-118108791-A | Synthetic method of Boc-Tyr (tBu) -Aib-Glu (OtBu) -Gly-OH | 成都普康唯新生物科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-118085016-A | Preparation method of D-phenylglycinyl-glycine | 天津卡普希科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117903082-A | Ionizable lipid JK-0042, preparation method, application and LNP encapsulation preparation method | 宁波君健生物科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-108908579-A | A method of promoting straw products color fastness | 安徽华宇工艺品股份有限公司 | 2018-11-30 | — | — | CN | claimed |
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | claimed |
| EP-3275864-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-01-31 | — | — | EP | claimed |
| CN-102093468-B | Method for synthesizing reduced glutathione | TIANJIN LIFALONG CHEMICAL TECHNOLOGY CO LTD | 2013-01-16 | — | — | CN | claimed |
| CN-101817860-B | Synthetic method of 13C marked glycocholic acid | SHANGHAI RES INST CHEMICAL IND | 2012-12-05 | — | — | CN | claimed |
| CN-102093468-A | Method for synthesizing reduced glutathione | TIANJIN LIFALONG CHEMICAL TECHNOLOGY CO LTD | 2011-06-15 | — | — | CN | claimed |
| CN-101817860-A | Synthetic method of 13C marked glycocholic acid | SHANGHAI RES INST CHEMICAL IND | 2010-09-01 | — | — | CN | claimed |
| EP-0636117-A4 | METHOD OF ADMINISTERING PYRUVATE AND METHODS OF SYNTHESIZING PYRUVATE PRECURSORS. | ABBOTT LAB (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0636117-A1 | USE OF PYRUVAMIDE AND SELECTED PYRUVYL-AMINO ACIDS | ABBOTT LABORATORIES (US) | 1995-02-01 | — | — | EP | claimed |
| WO-1993021147-A1 | METHOD OF ADMINISTERING PYRUVATE AND METHODS OF SYNTHESIZING PYRUVATE PRECURSORS | ABBOTT LABORATORIES (US) | 1993-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | EGLN3, EGLN2, P4HA1 | SLC6A2 3373/4885SLC6A3 2358/4885CA2 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.